title: Jazz Pharmaceuticals
id: 41421512
Jazz Pharmaceuticals plc a merger of Jazz Pharmaceuticals Inc and Azur Pharma plc is a global biopharmaceutical company with a focus on oncology and neuroscience It was founded in in California United States One of the company s considerable products is the United States Food and Drug Administration FDA approved drug Xyrem sodium oxybate the sodium salt of the naturally occurring neurotransmitter Hydroxybutyric acid GHB In net product sales of Xyrem were billion which represented of the company s total net product sales In Jazz was granted FDA approval to market Sunosi with indications for treating excessive daytime sleepiness EDS in narcolepsy as well as obstructive sleep apnea OSA In it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals br In the company pled guilty to felony charges related to its illegal marketing of Xyrem for off label use br The company is also a member of the Pharmaceutical Research and Manufacturers of America PhRMA br br br Company history and acquisitions br br br br On February the FDA accepted a new drug application for JZP Sodium oxybate for the treatment of Fibromyalgia In the following December a new patent was issued for Sodium Oxybate br On September Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc The Azur Pharma seat in Dublin became the headquarters of the combined company Azur Pharma had been marketing specialty pharmaceutical products in the central nervous system CNS and women s health areas with US operations in Philadelphia br On April the company acquired EUSA Pharma for million plus million in milestone payments In September the company sold its Women s Health business to Meda for million In December the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia br In January the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for billion br In May the company announced it would acquire Aliz Pharma II for million At the end of the same month the company announced its largest acquisition to date with the purchase of Celator Pharmaceuticals for billion As a result Jazz obtained the rights to breakthrough therapy Vyxeos liposomal daunorubicin and cytarabine for treatment of acute myeloid leukemia br In August the company announced it would acquire Cavion Inc for up to million br br br present br In January Jazz announced it would acquire GW Pharmaceuticals for US billion at per ADR in cash and in shares of Jazz br br br Acquisition history br The following is an illustration of the company s mergers acquisitions spin offs and historical predecessors br br br 